This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barkan, A. L. Search for Related Content PubMed PubMed Citation Articles by Barkan, A. L.

The "Quality of Life-Assessment of Growth Hormone Deficiency in Adults" Questionnaire: Can It Be Used to Assess Quality of Life in Hypopituitarism?¹

Departments of Internal Medicine and Surgery, University of Michigan and Veterans Administration Medical Centers, Ann Arbor, Michigan 48109

Address all correspondence and requests for reprints to: Ariel Barkan, M.D., 3920 Taubman Center, Box 0354, University of Michigan Medical Center, Ann Arbor, Michigan 48109-0354. E-mail: abarkan{at}umich.edu

Patients with hypopituitarism often have a multitude of physical and psychological complaints, collectively referred to as low quality of life (QoL). It has been asserted that GH deficiency (GHD) is the causative factor, and improved QoL scores have been reported during GH replacement. Qol-assessment of GHD (QoL-AGHDA) is the newest psychometric instrument with the purportedly high specificity for the issues encountered by patients with GHD. QoL-AGHDA was administered to 30 normal control subjects, 20 patients with severe GHD, and 22 patients with active acromegaly. QoL-AGHDA scores in controls (3.3 ± 0.7) were significantly (P < 0.001) different from those in patients with hypopituitarism with unsubstituted GHD (10.6 ± 1.5) and active acromegaly (11.6 ± 1.6). However, QoL-AGHDA was unable to discriminate between the latter two groups, one with GHD and the other with GH excess. We conclude that as QoL-AGHDA cannot distinguish between the extremes of GH output, its ability to detect an improvement in QoL during GH replacement has to be viewed with skepticism. This can be dispelled only by double blind, placebo-controlled studies.

This article has been cited by other articles:

				J. Moock, C. Albrecht, N. Friedrich, H. Volzke, M. Nauck, M. Koltowska-Haggstrom, T. Kohlmann, and H. Wallaschofski Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the Study of Health in Pomerania Eur. J. Endocrinol., January 1, 2009; 160(1): 17 - 24. [Abstract] [Full Text] [PDF]

				L. J. Woodhouse, A. Mukherjee, S. M. Shalet, and S. Ezzat The Influence of Growth Hormone Status on Physical Impairments, Functional Limitations, and Health-Related Quality of Life in Adults Endocr. Rev., May 1, 2006; 27(3): 287 - 317. [Abstract] [Full Text] [PDF]

				M. E. Molitch Diagnosis of GH Deficiency in Adults--How Good Do the Criteria Need to Be? J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 473 - 476. [Full Text] [PDF]

				R. D. Murray, K. H. Darzy, H. K. Gleeson, and S. M. Shalet GH-Deficient Survivors of Childhood Cancer: GH Replacement during Adult Life J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 129 - 135. [Abstract] [Full Text] [PDF]

				L. Prieto and M. Webb; Quality of Life Assessment in Patients with GH Deficiency and Acromegaly J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5996 - 5997. [Full Text] [PDF]